Form 4 for KYTX Kyverna Therapeutics, Inc.
Accepted 2025-04-15 00:00:00 ET · period of report 2025-04-11 · accession 0000950170-25-054342 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-04-15 | 2025-04-11 | KYTX | Walker Karen Marie | CTO | A - Grant | $0.00 | +13.0K | 22.6K | +135% | $0 |
| D | 2025-04-15 | 2024-04-11 | KYTX | Walker Karen Marie | CTO | A - Grant | $0.00 | +80.0K | 80.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-11 | A | A | 13,000 | $0.00 | 22,636 | D | — | — | (F1) Represents a restricted stock unit award of common stock, 1/4th of which shall vest on April 11, 2026, and 1/4th of which shall vest on each one-year anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| 2 | Derivative | Stock Option (right to buy) | 2024-04-11 | A | A | 80,000 | $0.00 | 80,000 | D | $2.06 · — to 2035-04-11 | 80,000 Common Stock | (F2) 1/4th of the shares subject to the option shall vest on April 11, 2026, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |